File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1136/annrheumdis-2013-eular.2454
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Lupus monocyte-derived dendritic cells treated with 1α,25-dihydroxyvitamin D3 and dexamethasone are tolerogenic and induce IL-10 producing regulatory T cells
Title | Lupus monocyte-derived dendritic cells treated with 1α,25-dihydroxyvitamin D3 and dexamethasone are tolerogenic and induce IL-10 producing regulatory T cells |
---|---|
Authors | |
Issue Date | 2013 |
Publisher | BMJ Publishing Group. The Journal's web site is located at http://ard.bmjjournals.com/ |
Citation | The 2013 Congress of the European League Against Rheumatism (EULAR), Madrid, Spain, 12-15 June 2013. In Annals of the Rheumatic Diseases, 2013, v. 72 suppl. 3, p. 825. abstract no. AB0131 How to Cite? |
Abstract | Background: The pathogenesis of systemic lupus erythematosus (SLE) is characterized by dysregulated dendritic cells (DCs) with over-production of type I interferon and hyperactive adaptive immune response. Clinical benefits of tolerogenic DCs have recently been shown in some murine models of immune mediated diseases.
Objectives: To examine if alternatively activated DCs (aaDCs) derived from SLE patients possess tolerogenic properties and to delineate the underlying mechanisms.
Methods: Lupus and healthy control aaDCs were generated by treating monocyte derived DCs using combination of 1α,25-Dihydroxyvitamin D3 (vitD3) and dexamethasone followed by maturation by lipopolysaccharide (LPS). These aaDCs were examined for phenotype and tolerogenic functions compared with LPS-matured DCs (matDCs). Activation markers and intracellular cytokine expression of T cells and/or DCs were measured by flow cytometry. ELISA was used to measure cytokine levels in supernatant. Western blot was performed for detection of RelB protein expression.
Results: Compared with matDCs, lupus aaDCs displayed semi-mature phenotype with low level of expression of co-stimulatory molecules and maturation markers (CD83, CD40), that remained stable despite challenge by CD40L, CpG-DNA and SLE serum. These aaDCs also possessed tolerogenic phenotype with suppressive effect on allogeneic T cell activation (CD25 and CD69 expression) and proliferation comparable to normal aaDCs. Lupus and normal aaDCs were shown to polarize normal and lupus naïve CD45RA+ T cells into T effector cells that were characterized by production of high level of IL-10, expression of Foxp3 mRNA and antigen-nonspecific suppressive effect on allogeneic third-party T cells. On the other hand, lupus and normal aaDCs skewed memory CD45RO+ T cells to less inflammatory phenotype with reduced expression of IFN-γ and IL-17. Although aaDCs displayed a cytokine profile of IL-12loIL-10hi, addition of neutralizing anti-IL-12 and exogenous IL-10 to culture conditions did not reverse the suppressive effect of aaDCs on activation and proliferation of allogeneic T cells, suggesting their tolerogenicity cannot be accounted by cytokine imbalance between IL-12 and IL-10. On the other hand, aaDCs were found to express reduced level of RelB, a transcription factor regulating DC differentiation and maturation.
Conclusions: Lupus aaDCs demonstrated tolerogenic properties with induction of IL-10 producing T cells that have regulatory functions. Reduced expression of RelB in aaDCs may be the underlying mechanism for their tolerogenicity.
Disclosure of Interest: None Declared |
Description | Session: SLE, Sjögren's and APS – etiology, pathogenesis and animal models |
Persistent Identifier | http://hdl.handle.net/10722/186811 |
ISSN | 2023 Impact Factor: 20.3 2023 SCImago Journal Rankings: 6.138 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wu, H | en_US |
dc.contributor.author | Luk, TW | en_US |
dc.contributor.author | Lam, KYI | en_US |
dc.contributor.author | Lau, WCS | en_US |
dc.contributor.author | Chan, WK | en_US |
dc.contributor.author | Mok, TMY | en_US |
dc.date.accessioned | 2013-08-20T12:21:07Z | - |
dc.date.available | 2013-08-20T12:21:07Z | - |
dc.date.issued | 2013 | en_US |
dc.identifier.citation | The 2013 Congress of the European League Against Rheumatism (EULAR), Madrid, Spain, 12-15 June 2013. In Annals of the Rheumatic Diseases, 2013, v. 72 suppl. 3, p. 825. abstract no. AB0131 | en_US |
dc.identifier.issn | 0003-4967 | - |
dc.identifier.uri | http://hdl.handle.net/10722/186811 | - |
dc.description | Session: SLE, Sjögren's and APS – etiology, pathogenesis and animal models | - |
dc.description.abstract | Background: The pathogenesis of systemic lupus erythematosus (SLE) is characterized by dysregulated dendritic cells (DCs) with over-production of type I interferon and hyperactive adaptive immune response. Clinical benefits of tolerogenic DCs have recently been shown in some murine models of immune mediated diseases. Objectives: To examine if alternatively activated DCs (aaDCs) derived from SLE patients possess tolerogenic properties and to delineate the underlying mechanisms. Methods: Lupus and healthy control aaDCs were generated by treating monocyte derived DCs using combination of 1α,25-Dihydroxyvitamin D3 (vitD3) and dexamethasone followed by maturation by lipopolysaccharide (LPS). These aaDCs were examined for phenotype and tolerogenic functions compared with LPS-matured DCs (matDCs). Activation markers and intracellular cytokine expression of T cells and/or DCs were measured by flow cytometry. ELISA was used to measure cytokine levels in supernatant. Western blot was performed for detection of RelB protein expression. Results: Compared with matDCs, lupus aaDCs displayed semi-mature phenotype with low level of expression of co-stimulatory molecules and maturation markers (CD83, CD40), that remained stable despite challenge by CD40L, CpG-DNA and SLE serum. These aaDCs also possessed tolerogenic phenotype with suppressive effect on allogeneic T cell activation (CD25 and CD69 expression) and proliferation comparable to normal aaDCs. Lupus and normal aaDCs were shown to polarize normal and lupus naïve CD45RA+ T cells into T effector cells that were characterized by production of high level of IL-10, expression of Foxp3 mRNA and antigen-nonspecific suppressive effect on allogeneic third-party T cells. On the other hand, lupus and normal aaDCs skewed memory CD45RO+ T cells to less inflammatory phenotype with reduced expression of IFN-γ and IL-17. Although aaDCs displayed a cytokine profile of IL-12loIL-10hi, addition of neutralizing anti-IL-12 and exogenous IL-10 to culture conditions did not reverse the suppressive effect of aaDCs on activation and proliferation of allogeneic T cells, suggesting their tolerogenicity cannot be accounted by cytokine imbalance between IL-12 and IL-10. On the other hand, aaDCs were found to express reduced level of RelB, a transcription factor regulating DC differentiation and maturation. Conclusions: Lupus aaDCs demonstrated tolerogenic properties with induction of IL-10 producing T cells that have regulatory functions. Reduced expression of RelB in aaDCs may be the underlying mechanism for their tolerogenicity. Disclosure of Interest: None Declared | - |
dc.language | eng | en_US |
dc.publisher | BMJ Publishing Group. The Journal's web site is located at http://ard.bmjjournals.com/ | - |
dc.relation.ispartof | Annals of the Rheumatic Diseases | en_US |
dc.rights | Annals of the Rheumatic Diseases. Copyright © BMJ Publishing Group. | - |
dc.title | Lupus monocyte-derived dendritic cells treated with 1α,25-dihydroxyvitamin D3 and dexamethasone are tolerogenic and induce IL-10 producing regulatory T cells | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Lau, WCS: cslau@hku.hk | en_US |
dc.identifier.email | Chan, WK: wkchanf@hku.hk | en_US |
dc.identifier.email | Mok, TMY: temy@hkucc.hku.hk | en_US |
dc.identifier.authority | Lau, WCS=rp01348 | en_US |
dc.identifier.authority | Mok, TMY=rp00490 | en_US |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1136/annrheumdis-2013-eular.2454 | - |
dc.identifier.hkuros | 217224 | en_US |
dc.identifier.volume | 72 | en_US |
dc.identifier.issue | suppl. 3 | en_US |
dc.identifier.spage | 825. abstract no. AB0131 | en_US |
dc.identifier.epage | 825. abstract no. AB0131 | en_US |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 0003-4967 | - |